Baker Bros. Advisors LP

Baker Bros. Advisors LP has filed trades across 32 companies (mainly through SEC (Form 4)), most often in Genomic Health Inc, Kodiak Sciences Inc. and Incyte Corp. The record holds 1,938 filings, for trades running from 7 January 2016 to 30 September 2026.

In open-market terms, that means 775 purchases worth €2.9B on one side and 741 sales worth €1.8B on the other. On balance, insiders were net buyers of €1.1B. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 298 share grants and 58 option exercises. Since January 2026: 82 purchases and 6 sales on the market.

In size, the median ticket on the buying side is €252k. As a share of market capitalisation, the median purchase stands at 0.0061%, based on 82 purchases. On 65 out of 655 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. For 435 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 69% of cases, with a median move of +12.0%. These figures describe past trades and do not predict future prices.

On 2 October 2026 came the latest disclosure, a share grant in Incyte Corp. The last purchase on record was published on 30 September 2026, which is 24 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.